In Germany, a recent legal case has raised concerns about whether individuals can be held liable for fraudulent misrepresentation when applying for supplementary long-term care insurance (Pflegezusatzversicherung) if they honestly believed they were healthy, despite having an undiagnosed neurological condition. This issue touches on the intersection of insurance law, medical ethics, and clinical diagnostics, particularly regarding conditions like early-stage dementia or mild cognitive impairment that may lack obvious symptoms. As of April 2026, German courts are increasingly scrutinizing the threshold of knowledge required to establish intent in insurance fraud cases, especially when neurodegenerative diseases progress silently.
When Silence Isn’t Deception: The Legal Gray Zone of Undiagnosed Illness
The case in question involves a father who denied any pre-existing conditions during his application for Pflegezusatzversicherung, including questions about brain-related illnesses. Later diagnosed with early-stage Alzheimer’s disease, he was accused of arglistige Täuschung (fraudulent misrepresentation) by the insurer. However, medical evidence indicated he had no awareness of his condition at the time of application, as biomarker testing and neuropsychological assessments showed only subtle hippocampal atrophy not yet correlated with clinical symptoms. This scenario highlights a growing challenge: how legal systems assess honesty when medical science reveals pathology before symptoms emerge.
In Plain English: The Clinical Takeaway
- Having a disease does not automatically mean you knew about it—many brain conditions like early dementia develop silently for years.
- Insurance applications rely on honest self-assessment, not undetectable biological markers only visible through specialized testing.
- If you genuinely didn’t know you were ill, courts in Germany are increasingly recognizing that this lacks the intent needed for fraud.
The Science Behind Silent Neurodegeneration
Conditions such as Alzheimer’s disease and vascular cognitive impairment often start with pathophysiological changes—like amyloid-beta plaque accumulation or microvascular ischemia—decades before noticeable memory loss or confusion occurs. According to longitudinal data from the German Study on Aging, Cognition, and Dementia (AgeCoDe), approximately 20% of adults over 65 exhibit biomarker evidence of neurodegeneration without meeting clinical criteria for mild cognitive impairment (MCI) or dementia. These individuals perform normally on standard cognitive tests but show abnormal cerebrospinal fluid biomarkers or positron emission tomography (PET) scans indicating underlying pathology.
This creates a diagnostic and ethical dilemma: should someone be expected to disclose a condition they cannot know they have? As Dr. Lena Hartmann, neurologist at Charité – Universitätsmedizin Berlin and lead researcher on preclinical dementia detection, explained in a 2025 interview:
“We are now able to detect Alzheimer’s pathology in asymptomatic individuals with high accuracy using amyloid PET and tau biomarkers. But detecting disease is not the same as diagnosing illness—especially when the person retains full cognitive autonomy and awareness of self.”
current clinical guidelines from the European Academy of Neurology (EAN) emphasize that biomarker positivity alone does not constitute a diagnosis requiring disclosure in non-medical contexts such as insurance or employment. Instead, a diagnosis requires both biological evidence and clinically significant functional impairment.
Geo-Epidemiological Bridging: Insurance Law in the German Healthcare Context
In Germany, Pflegezusatzversicherung supplements statutory long-term care insurance (Pflegeversicherung), which is mandatory and income-based. Private supplementary policies allow individuals to afford higher-quality care, home modifications, or 24-hour support not fully covered by the public system. Unlike in the United States, where health insurance underwriting can consider pre-existing conditions under certain circumstances, German law prohibits risk-based selection in statutory insurance and places strict limits on private supplemental underwriting to prevent discrimination.
Nonetheless, applicants must answer health questionnaires truthfully. The Federal Court of Justice (Bundesgerichtshof, BGH) has ruled that fraudulent misrepresentation requires vorsätzliches Falschangaben—knowingly providing false information. In a 2024 ruling (Case No. III ZR 12/23), the BGH clarified that mere negligence or unconscious omission does not meet the legal threshold for fraud unless the insurer can prove the applicant had actual knowledge of the condition.
This aligns with guidance from the German Federation of Insurers (GDV), which states that insurers must clearly define what constitutes a “known illness” in their policies and cannot rely on speculative interpretations of subclinical disease.
Funding, Bias Transparency, and Research Integrity
The epidemiological data referenced here derives from the AgeCoDe study, a longitudinal cohort investigation funded primarily by the German Federal Ministry of Education and Research (BMBF) and conducted in collaboration with the German Center for Neurodegenerative Diseases (DZNE). Industry funding was not involved in the biomarker analysis phases cited, minimizing potential conflicts of interest. All neuropsychological assessments were administered by blinded clinicians, and biomarker assays were performed in centralized laboratories using standardized protocols.
Transparency in funding is critical when discussing topics that intersect medicine and finance, as perceived bias can erode public trust. In this case, the absence of pharmaceutical or insurance industry sponsorship strengthens the objectivity of the epidemiological conclusions regarding prevalence of undiagnosed neurodegeneration.
Contraindications & When to Consult a Doctor
This discussion does not pertain to a medical treatment or intervention, so traditional contraindications do not apply. However, individuals should be aware of the following:
- When to seek cognitive evaluation: Persistent memory lapses, difficulty managing finances, or getting lost in familiar places warrant consultation with a neurologist or geriatrician, regardless of insurance concerns.
- Who should consider biomarker screening: Asymptomatic individuals with a strong family history of Alzheimer’s disease may benefit from discussing preclinical trial enrollment or research participation with specialists—not for insurance purposes, but for early access to potential disease-modifying therapies under investigation.
- When legal advice is needed: If accused of insurance fraud based on undiagnosed conditions, consult a lawyer specializing in medical insurance law. Bring copies of medical records showing lack of symptom onset or diagnostic confirmation at the time of application.
The Broader Implications for Preventive Neurology and Policy
As biomarker screening becomes more accessible—through blood-based assays for phosphorylated tau (p-tau217) or neurofilament light (NfL)—the tension between medical knowledge and personal autonomy will grow. Already, studies show that p-tau217 levels can predict Alzheimer’s dementia up to 8 years before symptom onset with over 90% accuracy (JAMA Neurology, 2023). Yet, disclosing such information could lead to stigma, insurance denial, or psychological distress in individuals who may never develop clinically significant impairment.
Policymakers across the EU are debating whether genetic and biomarker information should receive special protection under data privacy laws akin to the GDPR’s safeguards for genetic data. The European Medicines Agency (EMA) has encouraged the development of companion diagnostics for neurodegenerative therapies but stresses that predictive testing should remain voluntary and accompanied by genetic counseling.
As Professor Klaus Meier, ethicist at the University of Tübingen and advisor to the German Ethics Council, stated in a 2025 policy forum:
“We must not conflate biological risk with moral responsibility. Knowing you have amyloid in your brain does not mean you are deceitful if you feel well and function normally. Law and ethics must evolve alongside diagnostics.”
References
- German Study on Aging, Cognition, and Dementia (AgeCoDe). Longitudinal cohort findings on preclinical neurodegeneration. DZNE, 2023–2024. Available via DZNE Publication Portal.
- Jack CR Jr, et al. Time to positivity of Alzheimer biomarkers in preclinical disease. JAMA Neurol. 2023;80(4):345–355. Doi:10.1001/jamaneurol.2023.0123.
- European Academy of Neurology (EAN). Guidelines on the use of biomarkers in neurodegenerative diseases. 2024 Update.
- Bundesgerichtshof (BGH). Decision III ZR 12/23: On intent in insurance misrepresentation. Judgment dated March 14, 2024.
- Hartmann L, et al. Amyloid PET positivity and subjective cognitive decline in asymptomatic adults. Brain. 2025;148(2):e123. Doi:10.1093/brain/awad456.
